Summary of Relmada Therapeutics, Inc. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Cash Position: Closed 2025 with a cash balance of $93 million, including net proceeds of approximately $94 million from a stock offering in November 2025. Following a $160 million private financing in March 2026, the company expects to have sufficient resources to fund operations through 2029.

Expenses: Q4 2025 R&D expenses were $8.1 million, down from $11.0 million in Q4 2024, primarily due to the completion of two Phase III trials for REL-1017. General and administrative expenses rose to $12.3 million from $8.1 million year-over-year, driven by increased compensation costs.

Net Loss: Reported a net loss of $19.9 million for Q4 2025, or $0.27 per share, compared to a net loss of $18.7 million, or $0.06 per share, in Q4 2024.

2Strategic Updates and Business Highlights

NDV-01 Program: Significant progress with NDV-01, a sustained-release formulation for treating non-muscle invasive bladder cancer (NMIBC). The company reported a 12-month complete response rate of 76% in the Phase II study, with 80% in the BCG-unresponsive population.

Phase III RESCUE Program: FDA alignment achieved for two registrational pathways: one for adjuvant therapy in intermediate-risk bladder cancer and another for second-line treatment in BCG-unresponsive patients. The Phase III program is set to initiate mid-2026.

Cipranolone: Preparing to begin a proof-of-concept study in Prader-Willi syndrome in mid-2026, following previous proof of concept in Tourette syndrome.

Team Expansion: Strengthened development team with the appointment of Dr. Raj S. Pruthi as CMO, Oncology.

3Forward Guidance and Outlook

2026 Outlook: Anticipated as a pivotal year with the initiation of the Phase III RESCUE program for NDV-01 and the Phase II study for cipranolone. The company aims to provide updates on clinical progress and data at upcoming conferences, including AUA.

4Bad News, Challenges, or Points of Concern

Competitive Landscape: The NMIBC treatment space is becoming increasingly crowded with active trials and approved drugs, which could impact enrollment and market share.

Patient Population Concerns: Some questions arose regarding the classification of second-line patients and ensuring they meet the criteria, with concerns that they might be third-line patients instead.

Financial Losses: Continued net losses and increasing operational costs may raise concerns about the company’s financial sustainability in the long term.

5Notable Q&A Insights

Data Presentation: The company plans to present updated 12-month data at the AUA and aims for regular updates every three months as new data becomes available.

Enrollment Strategy: The management expressed confidence in the enrollment pace for the RESCUE program, citing the unique advantages of NDV-01's in-office administration.

Regulatory Feedback: The FDA has not stipulated a minimum follow-up duration for the second-line high-grade setting, focusing instead on the totality of the data presented. Overall, Relmada Therapeutics is positioned for significant clinical milestones in 2026, but faces challenges from a competitive market and ongoing financial losses.